Yumiko Wada

Summary

Publications

  1. pmc Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis
    Yumiko Wada
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 7:e35069. 2012
  2. ncbi Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor
    Yumiko Wada
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Blood 109:1156-64. 2007
  3. pmc Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis
    Hiroshi Keino
    Department of Ophthalmology, Kyorin University School of Medicine, 6 20 2 Shinkawa, Mitaka, Tokyo, 181 8611 Japan
    Arthritis Res Ther 10:R122. 2008
  4. doi Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib
    Jaime Acquaviva
    Synta Pharmaceuticals, Corp, Lexington, MA 02421, USA
    Mol Cancer Ther 11:2633-43. 2012
  5. pmc Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
    Suqin He
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Int J Oncol 42:35-43. 2013
  6. pmc Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Invest New Drugs 30:2201-9. 2012
  7. doi A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors
    Dan Zhou
    Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA Electronic address
    Toxicol Appl Pharmacol 273:401-9. 2013
  8. doi The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells
    Masazumi Nagai
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Free Radic Biol Med 52:2142-50. 2012
  9. doi Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy
    Weiwen Ying
    Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA
    Mol Cancer Ther 11:475-84. 2012

Collaborators

  • Dan Zhou
  • David A Proia
  • Yuan Liu
  • James G Krueger
  • Aaron B Kantor
  • Richard C Bates
  • Qin Huang
  • Suqin He
  • Jim Sang
  • Jaime Acquaviva
  • Julie C Friedland
  • Manuel Sequeira
  • Donald L Smith
  • Chaohua Zhang
  • Masazumi Nagai
  • Luisa Shin Ogawa
  • James Barsoum
  • Takayo Inoue
  • Weiwen Ying
  • Keizo Koya
  • Ronald K Blackman
  • Hiroshi Keino
  • Ayesha A Shafi
  • Nancy L Weigel
  • Lijun Sun
  • Dinesh Chimmanamada
  • Noriaki Tatsuta
  • Shuxia Ye
  • Kevin P Foley
  • Zhenjian Du
  • Nha H Vo
  • Britte C Beaudette-Zlatanova
  • Rongzhen Lu
  • Jamie Acquaviva
  • John Chu
  • Annabelle A Okada
  • Takayo Watanabe
  • Mamoru Niikura
  • Yasuhiko Sato

Detail Information

Publications9

  1. pmc Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis
    Yumiko Wada
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 7:e35069. 2012
    ..This study demonstrates the immunomodulatory activity of apilimod and provides clinical evidence supporting the inhibition of IL-12/IL-23 synthesis for the treatment of T(H)1- and T(H)17-mediated inflammatory diseases...
  2. ncbi Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor
    Yumiko Wada
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Blood 109:1156-64. 2007
    ..STA-5326 currently is being evaluated in phase 2 clinical trials in patients with Crohn disease and rheumatoid arthritis...
  3. pmc Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis
    Hiroshi Keino
    Department of Ophthalmology, Kyorin University School of Medicine, 6 20 2 Shinkawa, Mitaka, Tokyo, 181 8611 Japan
    Arthritis Res Ther 10:R122. 2008
    ..The purpose of this study was to determine if oral administration of the interleukin (IL) 12/IL-23 inhibitor, STA-5326, is effective in experimental autoimmune uveoretinitis (EAU)...
  4. doi Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib
    Jaime Acquaviva
    Synta Pharmaceuticals, Corp, Lexington, MA 02421, USA
    Mol Cancer Ther 11:2633-43. 2012
    ..Taken together, these data underscore the promise of ganetespib as a single-agent or combination treatment in KRAS-driven lung tumors...
  5. pmc Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
    Suqin He
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Int J Oncol 42:35-43. 2013
    ..Together these data suggest that further investigation of ganetespib as a new therapeutic treatment for prostate cancer patients is warranted...
  6. pmc Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Invest New Drugs 30:2201-9. 2012
    ..Taken together, these findings provide preclinical evidence for the use of this combination to treat patients with advanced NSCLC...
  7. doi A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors
    Dan Zhou
    Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA Electronic address
    Toxicol Appl Pharmacol 273:401-9. 2013
    ..Moreover, the results suggest that the retina/plasma exposure ratio and retinal elimination rate profiles of Hsp90 inhibitors, irrespective of their chemical class, may predict for ocular toxicity potential...
  8. doi The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells
    Masazumi Nagai
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Free Radic Biol Med 52:2142-50. 2012
    ..Together these findings highlight a unique mechanism of action with important implications for cancer therapy...
  9. doi Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy
    Weiwen Ying
    Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA
    Mol Cancer Ther 11:475-84. 2012
    ....